Of note, metyrapone, a potent inhibitor of 11-beta hydroxysteriod dehydroger and mineralocorticoid receptor as well as cytochrome P450, showed the highest negative enrichment score in cMAP analysis, implying that it maximally reversed the expression of upregulated CKD-related pathogenic genes in CAVD. The gene discussed is NR3C2; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.